Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2016 /
Target mutations in lung cancer

17th - 19th Nov 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.16
Views: 1324

Dr Romain Corre - Rennes University Hospital, Rennes, France

Dr Corre speaks with ecancertv at SIOG 2016 about his analysis of oncogenic drivers for geriatric lung cancer patients.

He describes how identifying mutational markers has improved treatment efficacy, and revealed pathways of resistance that new generations of therapy can overcome.

Dr Corre considers novel treatments against EGFR, ALK and BRAF mutations, among others, and the future promise of checkpoint immunotherapy.

This service has been kindly supported by an unrestricted grant from Merck/MSD.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation